AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1. (June 2017) - Neelapu, S.S.; Locke, F.L.; Bartlett, N.L.; Lekakis, L.J.; Miklos, D.; Jacobson, C.A.; Braunschweig, I.; Oluwole, O.; Siddiqi, T.; Lin, Y.; Timmerman, J.; Reagan, P.; et al.